Unified Patents v. Neurent Medical Ltd

Unified Patents, a member-based organization focused on deterring frivolous patent litigation by Non-Practicing Entities (NPEs) and improving patent quality, filed an Inter Partes Review (IPR) against Neurent Medical Ltd.. Neurent Medical Ltd. is a medical technology company specializing in innovative, minimally invasive treatments for chronic inflammatory sino-nasal diseases. Their primary product is the NEUROMARK® system, which uses radiofrequency energy to disrupt hyperactive autonomic nerves to alleviate chronic rhinitis symptoms.

The IPR, case number IPR2025-01125, challenged U.S. Patent 12089889, owned by Neurent Medical Ltd. The patent generally relates to devices and methods for treating chronic rhinitis by modulating nasal nerves, specifically through radiofrequency ablation of the posterior nasal nerve to reduce inflammation and symptoms. The procedural posture of this case is before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). This venue is critical as IPRs offer a faster and often more cost-effective alternative to district court litigation for challenging patent validity based on prior art patents and printed publications.

The case is notable because the IPR petition was "Not Instituted - Procedural." This means the PTAB, after reviewing the petition, declined to initiate a full review of the patent's claims, not necessarily due to the merits of the invalidity arguments, but for other discretionary or statutory reasons. Such procedural denials can arise from factors like the pendency of parallel district court litigation (under the Fintiv factors), prior art or arguments already considered by the USPTO, or issues related to identifying the real party-in-interest. Unified Patents frequently utilizes IPRs as a core strategy to challenge patents asserted by NPEs, aiming to increase the costs for these entities and deter the assertion of low-quality patents. The non-institution of this IPR on procedural grounds means Neurent Medical's patent will not undergo PTAB review in this instance, which can be a significant outcome for the patent owner, potentially preserving the patent's validity against this particular challenge.Unified Patents, a member-based organization dedicated to improving patent quality and deterring patent assertions by Non-Practicing Entities (NPEs), initiated an Inter Partes Review (IPR) against Neurent Medical Ltd.. Neurent Medical Ltd. is a medical technology company based in Ireland and the U.S., which develops innovative, minimally invasive treatments for chronic inflammatory sino-nasal diseases. Their flagship product, the NEUROMARK® system, utilizes radiofrequency energy to precisely disrupt hyperactive autonomic nerves in the nasal cavity, aiming to provide durable relief for patients suffering from chronic rhinitis.

The IPR, designated IPR2025-01125, targeted U.S. Patent 12089889, owned by Neurent Medical Ltd. While the specific technical claims challenged in the petition are not detailed, the patent generally pertains to devices and methods for treating chronic rhinitis through the modulation of nasal nerves, often involving radiofrequency ablation of the posterior nasal nerve to mitigate inflammation and symptoms. The procedural posture of this case places it before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). This forum is a critical venue for challenging patent validity based on prior art consisting of patents or printed publications, often providing a more streamlined and cost-efficient process compared to district court litigation.

This case is notable because the IPR petition was "Not Instituted - Procedural." This outcome signifies that the PTAB, after its initial review, declined to proceed with a full merits review of the patent's claims, but did so based on procedural or discretionary grounds rather than a determination of the merits of the invalidity arguments. Common procedural reasons for denying institution include discretionary factors such as the existence of parallel district court litigation involving the same patent (often evaluated under the Fintiv factors), or issues related to the proper identification of real parties-in-interest. Unified Patents' core strategy involves using IPRs to challenge patents asserted by NPEs, aiming to increase the risk and cost for these entities and deter the assertion of allegedly low-quality patents. In this instance, the procedural denial means Neurent Medical's patent avoids a PTAB review of its patentability, a significant advantage for the patent owner as it preserves the patent against this particular challenge.

The user's request is to list key legal developments for "this patent infringement litigation." However, the case provided, Unified Patents v. Neurent Medical Ltd, IPR2025-01125, is an Inter Partes Review (IPR) proceeding at the Patent Trial and Appeal Board (PTAB), not a district court patent infringement litigation. IPRs are administrative proceedings to challenge patent validity, not to litigate infringement.

While IPR2025-01125 itself is not an infringement litigation, the provided search results indicate that there is a related district court patent infringement case where Neurent Medical Ltd is asserting patents, including US12089889, against Aerin Medical Inc. This appears to be Neurent Medical Ltd. v. Aerin Medical Inc., C.A. No. 24-1070-JLH (D. Del.), which was later consolidated with Aerin Medical Inc. et al v. Neurent Medical Inc. et al, 1:2023cv00756-JLH (D. Del.). It also seems that Aerin Medical Inc. filed several IPRs, including IPR2025-01125, challenging Neurent's patents.

Therefore, to address the user's request comprehensively, I will first detail the IPR proceeding IPR2025-01125, and then outline the developments in the parallel district court patent infringement litigation where US12089889 is at issue, and how the IPRs have affected it.

I. Inter Partes Review (IPR) Proceeding: Unified Patents v. Neurent Medical Ltd, IPR2025-01125

Unified Patents filed an Inter Partes Review petition against Neurent Medical Ltd, challenging US Patent 12089889. This petition was among a series of IPRs that faced a high rate of procedural denials by the USPTO Director in late 2025, following a shift in the PTAB's procedures for institution decisions.

• Filing of Petition: The exact filing date for IPR2025-01125 is not explicitly stated in the provided snippets, but other IPRs challenging Neurent patents, such as IPR2025-01126 and IPR2025-01127, were filed by Aerin Medical Inc. in June 2025. Given the similar case number, it's likely IPR2025-01125 was filed around the same period.
• Patent at Issue: US Patent 12089889.
• Outcome: The petition was Not Instituted - Procedural. This non-institution decision occurred around November 2025. The denial of institution for IPR2025-01125, along with other related IPRs challenging Neurent patents, was likely a discretionary denial by the USPTO Director. This period saw a significant increase in procedural denials by the PTAB Director, who assumed personal control over all IPR and PGR institution determinations in October 2025 and often issued summary decisions without detailed reasoning. Arguments for discretionary denial in similar cases included the petitioner's delay in filing IPR petitions after patent assertion and the existence of parallel district court proceedings with overlapping invalidity contentions.

II. Parallel District Court Patent Infringement Litigation: Neurent Medical Ltd. v. Aerin Medical Inc. (D. Del.)

Neurent Medical Ltd. is involved in a patent infringement lawsuit where it has asserted US Patent 12089889, among others, against Aerin Medical Inc. This case began in the District of Delaware.

• Filing & Initial Pleadings:

  • July 11, 2023: Aerin Medical Inc. and The Foundry, LLC filed a patent infringement case against Neurent Medical Inc. and Neurent Medical Ltd. in the District of Delaware, Aerin Medical Inc. et al v. Neurent Medical Inc. et al, 1:2023cv00756-JLH.
  • September 24, 2024: Neurent Medical Ltd. filed its own action asserting infringement by Aerin Medical Inc. of US Patent Nos. 12,096,973; 12,096,974; and 12,098,889 (which includes US12089889) in Neurent Medical Ltd. v. Aerin Medical Inc., C.A. No. 24-1070-JLH (D. Del.).
  • March 18, 2025: The two cases (1:2023cv00756 and 1:24-1070) were consolidated.
  • Motions to Dismiss: Aerin Medical Inc.'s motion to dismiss claims asserted by Neurent (in the 1070 Action) was pending as of September 12, 2025. Neurent also filed answering briefs in opposition to a motion to consolidate cases and stay, and a motion to dismiss for failure to state a claim around December 2024.

• Claim Construction (Markman) Outcomes: The provided information does not detail any specific Markman hearing or claim construction outcomes for this litigation. However, in related IPR proceedings, it was noted that claim terms are construed using the same standard as in civil actions, with parties sometimes asserting no need for construction if invalidity is clear.

• Discovery Milestones with Strategic Significance: The consolidated order in March 2025 included "interim dates for discovery on the Neurent Patents to get them 'caught up' to where discovery was on the Aerin/Foundry Patents at the time of the consolidation".

• Trial Events, Verdict, and Post-Trial Motions: The litigation has not reached the trial stage yet.

• Settlement, Dismissal, Judgment, or Appeal: The case is still active and ongoing.

• Parallel PTAB IPR/PGR Proceedings and their effect on the Litigation:

  • July 2024: The PTAB instituted IPRs with respect to patents owned by Aerin/The Foundry that Neurent had challenged (e.g., IPR2024-00277 where claims of US Patent 11,241,271 B2 were found unpatentable on July 11, 2025).
  • August 8, 2024: The district court entered a stipulation staying the action in its entirety (including claims related to Aerin/Foundry Patents and Neurent's defenses and counterclaims related to Neurent's '262 patent, tortious interference, and unfair competition) until the PTAB issued Final Written Decisions in the IPRs related to the Aerin/Foundry Patents.
  • June 2025: Aerin Medical Inc. filed petitions for Inter Partes Review challenging all claims of the Neurent Patents, including US12089889. These IPRs were expected to have institution decisions by January 8, 2026.
  • October/November 2025: Several IPRs filed by Aerin challenging Neurent's patents, including IPR2025-01125 (Unified Patents' IPR), IPR2025-01126, and IPR2025-01127, were subject to discretionary denial by the USPTO Director. The Director's decisions to deny institution were often summary and did not provide detailed reasoning, a trend that significantly increased procedural denials at the PTAB. This discretionary denial was sometimes based on arguments that the petitioner waited nearly a year after assertion to file IPR petitions and had overlapping invalidity arguments in district court.
  • The parties agreed that the stay of Aerin and The Foundry's infringement claims regarding their patents should remain through any appeals of the Final Written Decisions in the IPRs involving those patents. However, other claims or counterclaims in the case were not to remain stayed. The non-institution of IPR2025-01125 and similar IPRs means that the validity of US12089889, on the grounds raised in those IPRs, will likely be determined in the ongoing district court litigation.

Despite extensive searching of publicly available dockets, firm websites, and legal news outlets, the specific counsel of record representing Unified Patents in IPR2025-01125 against Neurent Medical Ltd for U.S. Patent 12089889 could not be definitively identified.

Unified Patents frequently utilizes a combination of in-house counsel and external law firms for its inter partes review (IPR) proceedings. For example, in a separate IPR (IPR2021-01260, Unified Patents, LLC v. Authwallet LLC), Unified Patents was represented by attorneys from Erise IP, P.A. and its own in-house counsel, including Jason R. Mudd, Kelly R. Hughes, Eric A. Buresh of Erise IP, P.A., and Roshan Mansinghani and Jordan M. Rossen of Unified Patents LLC.

Given that IPR2025-01125 was "Not Instituted - Procedural," detailed attorney appearances or the full petition document listing counsel may not be as readily available in public search results as for cases that proceed further. Therefore, the specific attorneys for this particular IPR are not publicly discernible from the conducted research.

While direct docket entries for IPR2025-01125 specifically identifying counsel for Neurent Medical Ltd. were not immediately available, information from a closely related Inter Partes Review, IPR2025-01126 (Aerin Medical Inc. v. Neurent Medical Ltd.), indicates that Wilmer Cutler Pickering Hale Dorr LLP represents Neurent Medical Ltd.. It is a common practice for a patent owner to retain the same legal team for multiple IPR proceedings, particularly when they are filed around the same time and involve similar subject matter.

Based on the available information, the following counsel is likely representing Neurent Medical Ltd. in IPR2025-01125:

David L. Cavanaugh

• Role: Likely Lead Counsel (based on extensive IPR experience)
• Firm: Wilmer Cutler Pickering Hale Dorr LLP
• Office Location: Washington, D.C.
• Relevant Experience: Mr. Cavanaugh has broad experience in intellectual property practice, including IP litigation and patent procurement. He has extensive experience in post-grant proceedings at the US Patent Office, serving as lead counsel or counsel of record on over 120 inter partes review (IPR) proceedings and presenting at more than a dozen oral hearings at the Patent Trial and Appeal Board (PTAB). He is recognized in The Best Lawyers in America® 2026 for Litigation - Patent and Patent Law. He also previously served as a senior patent counsel at Boston Scientific Corporation and as a patent examiner at the Patent Office.

Wilmer Cutler Pickering Hale Dorr LLP

• Firm Locations: WilmerHale is an international law firm with co-headquarters in Washington, D.C., and Boston, Massachusetts, and other offices in locations such as New York, Palo Alto, London, and Berlin.
• Relevant Experience: WilmerHale is a prominent firm with extensive experience in patent litigation and intellectual property matters.